Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2023-04-04 00:00:00 ET · period of report 2023-04-03 · accession 0001209191-23-022777 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-04 | 2023-04-03 | VIR | De Backer Marianne | CEO | A - Grant | $0.00 | +576.5K | 576.5K | New | $0 |
| D | 2023-04-04 | 2023-04-03 | VIR | De Backer Marianne | CEO | A - Grant | $0.00 | +1.15M | 1.15M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-03 | A | A | 576,452 | $0.00 | 576,452 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-04-03 | A | A | 1,152,904 | $0.00 | 1,152,904 | D | $23.28 · — to 2033-04-02 | 1,152,904 Common Stock | (F2) 25% of the shares subject to the stock option vest and become exercisable on April 3, 2024, and the remainder vest in 36 equal monthly installments thereafter. |